IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

NCT07217301 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

iO Resistant sqNSCLC

Interventions

DRUG: IBI363
DRUG: Control Arm

Sponsor

Fortvita Biologics (USA)Inc.

Collaborators

[object Object]
[object Object]